The portfolio page was updated to reflect the addition of axatilimab 4 CSF-1R 1L chronic GVHD status for mobile GVHD and the addition of axatilimab 4 CSF-1R 1L chronic GVHD | + ruxolitinib status for mobile Lymphomas/Leukemias.
What changed on the page
The updated program listings include “axatilimab 4 CSF-1R 1L chronic GVHD status for mobile GVHD” and “axatilimab 4 CSF-1R 1L chronic GVHD | + ruxolitinib status for mobile Lymphomas/Leukemias.”
What this signalsWebsite changes often show new positioning, products or customers.
website-intelligenceproductUpdateGet every website changes signal for Incyte and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Incyte this week?”
The Signal API returns website changes signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full website-intelligence record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/15f2d0f7-1196-5dfc-89b7-41a8fd81ae4e returns this record as JSON. POST /v1/companies/enrich returns every signal for incyte.com.
{
"signal_id": "15f2d0f7-1196-5dfc-89b7-41a8fd81ae4e",
"signal_type": "website-intelligence",
"signal_subtype": "productUpdate",
"detected_at": "2026-08-17T00:00:00+00:00",
"company": {
"name": "Incyte",
"domain": "incyte.com"
},
"data": {
"summary": "The portfolio page was updated to reflect the addition of axatilimab 4 CSF-1R 1L chronic GVHD status for mobile GVHD and the addition of axatilimab 4 CSF-1R 1L chronic GVHD | + ruxolitinib status for mobile Lymphomas/Leukemias.",
"evidence": "The updated program listings include “axatilimab 4 CSF-1R 1L chronic GVHD status for mobile GVHD” and “axatilimab 4 CSF-1R 1L chronic GVHD | + ruxolitinib status for mobile Lymphomas/Leukemias.”",
"relevance": 0.69,
"source_url": "https://www.incyte.com/what-we-do/pharmaceutical-portfolio",
"impact_rationale": "These additions demonstrate continued investment in oncology and hematologic-growth programs, with ruxolitinib status indicating a differentiated treatment option for leukemia."
}
}
curl https://signals.autobound.ai/v1/signals/15f2d0f7-1196-5dfc-89b7-41a8fd81ae4e \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.